Gene Therapy Delivery
Gene Therapy Delivery - Related Videos
05:00
Ex Vivo Culture of Patient Tissue & Examination of Gene Delivery
0 Views •
Cited by 4 •
2010
This article describes the culture of patient tissue slices for gene delivery studies and subsequent analysis of gene expression using IVIS bioluminescence imaging.
01:22
Gene Therapy
0 Views •
2021
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
01:22
Gene Therapy
0 Views •
2026
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
07:48
An Orthotopic Bladder Cancer Model for Gene Delivery Studies
0 Views •
Cited by 9 •
2013
Implantation of cancer cells into the organ of origin can serve as a useful preclinical model to evaluate novel therapies. MB49 bladder carcinoma cells can be grown within the bladder following intravesical instillation. This protocol demonstrates catheterization of the mouse bladder for the purpose of tumor implantation and adenoviral delivery.
05:12
Subpial Gene Delivery in the Mouse Spinal Cord to Evaluate Gene Expression
0 Views •
2025
Source: Tadokoro, T., et al. Subpial Adeno-associated Virus 9 (AAV9) Vector Delivery in Adult Mice. J. Vis. Exp. (2017)This video demonstrates a subpial injection technique for gene delivery to the spinal cord in mice. The procedure involves exposing the dura mater, puncturing the pia mater, and injecting a recombinant adeno-associated virus (rAAV) carrying a fluorescent protein-expressing gene into the subpial space. Following injection and recovery, the virus facilitates gene expression in...
FAQs
Success depends on more than transporting genetic material. The delivery system must protect DNA or RNA, reach the intended tissue, enter the relevant cells, and release its cargo in a usable form. It must also limit immune responses and overcome restricted access to particular organs. Failure at any stage can reduce therapeutic expression or treatment durability.
Viral vectors and nonviral carriers are alternative platform classes for transporting therapeutic genetic material. Both must support protection, tissue access, cellular entry, and cargo release, but their development involves addressing barriers such as immune responses, organ-specific delivery, expression, and durability. Comparing these platforms therefore focuses on how effectively each meets the requirements of a particular medical use.
Tissue specificity, cellular entry, cargo release, immune responses, and the duration of genetic activity all influence effectiveness. Delivery must reach the relevant organ and cells while preserving the genetic material and making it available inside those cells. These factors determine whether treatment can produce sufficient expression, silence a target gene, or modify gene activity for an appropriate period.
A development strategy generally considers cargo protection first, followed by transport to the target tissue, entry into the intended cells, and release of the DNA or RNA. Researchers then assess whether the genetic material produces the desired replacement, silencing, or modification of gene activity. Immune responses, organ access, expression, and durability help determine whether the approach is suitable.
Medical research investigates these approaches for inherited disorders, cancer, and other diseases in which changing gene activity could provide therapeutic benefit. The delivery strategy must be matched to the relevant tissue and treatment goal, because effective medicine depends on reaching appropriate cells and achieving useful, sufficiently durable genetic expression or modification.
Improved delivery aims to increase tissue specificity, support effective expression, and extend treatment durability while controlling genetic material in the body. Researchers also seek to reduce limitations from immune responses and restricted access to particular organs. Together, these outcomes help determine whether a gene-based treatment can move from a genetic concept toward an effective medicine.